|
Allarity Therapeutics, Inc. (AllR) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Allarity Therapeutics, Inc. (ALLR) Bundle
Ingementista para su precisión, nuestra calculadora DCF (ALLR) le permite evaluar la valoración de Allarity Therapeutics, Inc. utilizando información financiera en tiempo real y una flexibilidad completa para modificar parámetros cruciales para un mayor pronóstico.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -100 | 0 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -15.6 | -6.0 | -25.9 | -17.2 | -12.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -12983.33 | 100 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .1 | .1 | .1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 70.83 | 100 | 100 | 100 | 100 | 94.17 | 94.17 | 94.17 | 94.17 | 94.17 |
| EBIT | -15.7 | -6.1 | -26.0 | -17.4 | -12.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -13054.17 | 100 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 1.5 | .3 | 19.6 | 2.0 | .2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.7 | 1.1 | 1.3 | .9 | .9 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 1381.67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | -1.3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | -1.67 | 100 | 100 | 100 | 100 | 79.67 | 79.67 | 79.67 | 79.67 | 79.67 |
| Accounts Payable | 2.2 | 2.1 | .7 | 6.3 | 8.4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 1815 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -6.67 | 100 | 100 | 100 | 100 | -1.33 | -1.33 | -1.33 | -1.33 | -1.33 |
| Tax Rate, % | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 |
| EBITAT | -11.9 | -4.3 | -26.1 | -15.9 | -11.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -11.3 | -3.7 | -26.3 | -11.1 | -9.3 | -7.5 | .0 | .0 | .0 | .0 |
| WACC, % | 5.84 | 5.84 | 5.84 | 5.84 | 5.84 | 5.84 | 5.84 | 5.84 | 5.84 | 5.84 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -7.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -7 | |||||||||
| Net Debt | 1 | |||||||||
| Equity Value | -8 | |||||||||
| Diluted Shares Outstanding, MM | 1,991 | |||||||||
| Equity Value Per Share | 0.00 |
What You Will Get
- Real ALLR Financial Data: Pre-filled with Allarity Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Allarity Therapeutics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Accurate Financial Data: Gain access to reliable historical performance and future estimates for Allarity Therapeutics, Inc. (ALLR).
- Tailored Forecast Inputs: Modify highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Clear and concise charts and summaries to help you interpret your valuation findings.
- Designed for All Skill Levels: An intuitive format suitable for investors, CFOs, and consultants alike.
How It Works
- Download: Get the ready-to-use Excel file containing Allarity Therapeutics, Inc.'s (ALLR) financial data.
- Customize: Modify forecasts, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly compare the results.
- Make Decisions: Leverage the valuation findings to inform your investment approach.
Why Choose Allarity Therapeutics, Inc. (ALLR) Calculator?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Allarity Therapeutics.
- Customizable Inputs: Modify yellow-highlighted fields to explore different financial scenarios for (ALLR).
- Detailed Insights: Automatically computes Allarity's intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and consultants focusing on (ALLR).
Who Should Use This Product?
- Investors: Accurately assess Allarity Therapeutics, Inc.'s (ALLR) fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Allarity Therapeutics, Inc. (ALLR).
- Consultants: Easily modify the template for valuation reports tailored to Allarity Therapeutics, Inc. (ALLR) clients.
- Entrepreneurs: Acquire insights into financial modeling practices used by leading biotech firms like Allarity Therapeutics, Inc. (ALLR).
- Educators: Employ it as a teaching resource to illustrate valuation techniques relevant to Allarity Therapeutics, Inc. (ALLR).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Allarity Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Allarity Therapeutics, Inc. (ALLR).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.